



Using Blood Tests to Detect Cancer Early

Alliance A212102

Here's how **you** can help.
Consider the **Alliance MCED Biobank Study**.

What is the Alliance MCED Biobank Study?

The Alliance Multicancer Early Detection (MCED) Biobank Study is a clinical trial that aims to obtain a reference set of blood samples from newly diagnosed patients with cancer and healthy individuals without cancer to include in a future trial to assess early cancer detection blood tests.

How does the Alliance MCED Biobank Study work?

The Alliance MCED Biobank Study plans to enroll about 2,000 people across several health systems. Participants will have a blood sample collected and will complete a health questionnaire. Participants with cancer will have an option to provide a tissue sample. All participants will be asked to provide another blood sample after 1 year.

Why should I participate?

Despite many advances, cancer remains the second leading cause of death worldwide. Today, there is no screening available for the majority of life threatening cancers, and as a result, most cancers are not detected until too late when outcomes are poor. The earlier cancer is diagnosed, the better the chance of successful treatment, but cancer can spread and grow before any symptoms arise.

The Alliance MCED Biobank Study will contribute to a greater understanding of how to detect multiple types of cancer through early detection blood tests by looking for signals of cancer that may be present. These tests may be done in routine health care to help more people increase their chances of finding cancer early when treatment is more likely to be successful.

While you will not be compensated for participating in this study, your participation in clinical trials could make a difference for your family and your community, as well as improve treatment outcomes for patients with cancer around the world.

Who is eligible to participate?

The study is currently open to men and women aged 40 to 75 years who are either:

- Healthy individuals without cancer.
- Individuals with untreated cancer.
- Individuals who may have cancer.

  Cancers in the study: bladder, breast, colorectal, endometrial, esophageal, gastric, head or neck, hepatobiliary, kidney, leukemia, lung, lymphoma, melanoma, multiple myeloma, ovarian, pancreatic, prostate, sarcoma, thyroid, sarcoma, or uterine.

Individuals must be willing to provide a blood sample and informed consent to participate in the study. In addition, individuals must be able to read and understand English or Spanish.

What is a clinical study?

Clinical studies (or trials) are a type of research involving patient volunteers. They are designed to find better ways to treat disease.

Am I required to be in this study?

No. Taking part in this study is voluntary. You are free to choose to participate, not to participate, or to leave the study at any time.

How do I participate?

If you are interested in this study, or if you have a friend or family member who is interested in this study, talk to your doctor or nurse to discuss the possible benefits and risks of participating.

Who is conducting this study?

This study is being conducted by the Alliance for Clinical Trials in Oncology. Alliance is part of a national research network funded by the National Cancer Institute (NCI).

Where can I get more information?

For more information, contact the NCI Cancer Information Service toll-free at 1-800-422-6237 or visit their website at www.cancer.gov (search "A212102"). You can find information on the Alliance website at www.AllianceforClinicalTrialsinOncology.org or Clinicaltrials.gov; search "NCT05334069."

You can also talk to the hospital staff who provided this handout if you are interested in learning more.

Contact the UMSJMC Office of Clinical Research by phone: 410 427 5459 or by email: UMSJMCTrials@umm.edu



NCI Community Oncology Research Program

A program of the National Cancer Institute of the National Institutes of Health

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY